Coccidioidomycosis is a potentially life-threatening mycosis endemic to the Southwestern USA and some arid regions of Central and South America. A vaccine against Coccidioides infection would benefit over 30-million people who reside in or visit the endemic regions. Vaccine candidates against systemic fungal infections come in many forms. Live attenuated vaccines are derived from disease-causing pathogens and generally stimulate excellent protective immunity. Since attenuated vaccines contain living microbes, there is a degree of unpredictability raising concerns regarding safety and stability. Generation of a subunit vaccine has initiated efforts to design a safe reagent suitable for administration to humans at risk of coccidioidomycosis. Epitope-based vaccines allow for eliciting specific protective immune responses and removal of potentially detrimental sequences to improve safety. This chapter describes methods for the identification of T cell epitopes derived from Coccidioides antigens, design, and production of a recombinant vaccine containing multiple T cell epitopes, and evaluation of its protective efficacy and vaccine immunity against pulmonary Coccidioides infection using a strain of transgenic mice that express a human MHC II molecule.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-4939-7104-6_4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mistaken for migraine: Coccidioidal meningitis.
JAAPA
February 2025
At the time this article was written, Anna Morgan was a student in the PA program at the University of North Texas Health Science Center (UNT HSC) in Fort Worth, Tex. She now practices in urgent care at Dignity Health-Mercy Medical Group in Sacramento, Calif. Stephen James Hoyt is a hospitalist at the John Peter Smith Hospital in Fort Worth. Jamie Park practices in emergency medicine and is an assistant professor in the PA program at UNT HSC. Vic Holmes is an associate professor in the PA program at UNT HSC, specializes in the field of family medicine, and is chair of the North Texas Regional Institutional Review Board. The authors have disclosed no potential conflicts of interest, financial or otherwise.
The incidence of coccidioidomycosis has been rising in the past decade. This case report focuses on a man with a history of persistent migraine who presented to the ED with altered mental status. After cerebrospinal fluid testing, the patient was diagnosed with coccidioidal meningitis and treated with lifelong antifungal therapy.
View Article and Find Full Text PDFImpact of fluconazole on outcomes of patients with primary pulmonary coccidioidomycosis: a commercial health insurance claims-based, propensity score matched analysis.
Clin Infect Dis
January 2025
Department of Medicine, Division of Infectious Diseases, and the Department of Medical Microbiology and Immunology, University of California, Davis, Sacramento, California, USA.
Background: Patients with pulmonary coccidioidomycosis often experience prolonged symptoms lasting weeks to months. Limited data exist regarding whether fluconazole prevents development of disseminated disease or shortens symptom duration. We describe factors associated with fluconazole receipt and assess its effect on outcomes among patients with pulmonary coccidioidomycosis.
View Article and Find Full Text PDFCoccidioidal Meningitis in a Patient With HIV.
Cureus
December 2024
Family Medicine Alexandria, Louisiana State University Health Sciences Center, Alexandria, USA.
Coccidioidal meningitis is a rare yet life-threatening complication of disseminated infection, primarily affecting immunocompromised individuals. and are dimorphic fungi endemic to the southwestern United States, where exposure to inhaled spores can lead to a range of clinical manifestations, including pulmonary and central nervous system (CNS) involvement. This report describes the case of a 27-year-old correctional officer with advanced human immunodeficiency virus (HIV) infection who presented with chronic headaches, altered mental status, and significant weight loss following his relocation from Arizona to Louisiana.
View Article and Find Full Text PDFImmune Reconstitution Inflammatory Syndrome-Induced Thrombocytopenia in a Patient With HIV and Coccidioidomycosis.
Cureus
December 2024
Internal Medicine, Kern Medical, Bakersfield, USA.
Highly active antiretroviral therapy (HAART) is imperative in managing human immunodeficiency virus (HIV) infections. HAART aims to inhibit viral replication and improve immunity. Antiretroviral therapy has led to significant improvement in CD4-T cell counts and reductions in viral load, leading to improved overall immune function, increased survival, and decreased frequency of opportunistic infections.
View Article and Find Full Text PDFValley-Forecast: Forecasting Coccidioidomycosis incidence via enhanced LSTM models trained on comprehensive meteorological data.
J Biomed Inform
January 2025
Department of Computer Science, University of Idaho, Moscow, ID 83844, United States of America. Electronic address:
Coccidioidomycosis (cocci), or more commonly known as Valley Fever, is a fungal infection caused by Coccidioides species that poses a significant public health challenge, particularly in the semi-arid regions of the Americas, with notable prevalence in California and Arizona. Previous epidemiological studies have established a correlation between cocci incidence and regional weather patterns, indicating that climatic factors influence the fungus's life cycle and subsequent disease transmission. This study hypothesizes that Long Short-Term Memory (LSTM) and extended Long Short-Term Memory (xLSTM) models, known for their ability to capture long-term dependencies in time-series data, can outperform traditional statistical methods in predicting cocci outbreak cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!